Loop-Mediated Isothermal Amplification (LAMP) Diagnostic Equipment Manufacturing in 2025: Innovations, Market Dynamics, and the Road Ahead. Discover How LAMP Technology is Shaping the Next Era of Rapid Diagnostics.
- Executive Summary: Key Trends and Market Drivers in 2025
- Global Market Size, Segmentation, and 2025–2030 Growth Forecasts
- Technological Innovations in LAMP Diagnostic Equipment
- Competitive Landscape: Leading Manufacturers and New Entrants
- Regulatory Environment and Quality Standards (e.g., FDA, CE Mark)
- Applications: Infectious Disease, Food Safety, and Beyond
- Supply Chain, Manufacturing Challenges, and Solutions
- Regional Analysis: North America, Europe, Asia-Pacific, and Emerging Markets
- Strategic Partnerships, M&A, and Investment Trends
- Future Outlook: Market Opportunities and Projected CAGR (2025–2030)
- Sources & References
Executive Summary: Key Trends and Market Drivers in 2025
The Loop-Mediated Isothermal Amplification (LAMP) diagnostic equipment manufacturing sector is poised for significant growth in 2025, driven by the convergence of technological innovation, expanding clinical applications, and global health priorities. LAMP technology, which enables rapid and sensitive nucleic acid amplification at a constant temperature, continues to gain traction as a preferred method for point-of-care (POC) diagnostics, particularly in infectious disease detection and resource-limited settings.
A key trend shaping the market is the increasing demand for decentralized and rapid diagnostic solutions. The COVID-19 pandemic accelerated the adoption of LAMP-based platforms, and this momentum persists as healthcare systems seek robust, field-deployable tools for ongoing surveillance of respiratory, vector-borne, and emerging pathogens. Companies such as Eiken Chemical Co., Ltd., the original developer of LAMP technology, remain at the forefront, supplying both reagents and integrated diagnostic systems globally. Eiken’s Loopamp series continues to set industry benchmarks for reliability and ease of use.
Another major driver is the integration of LAMP with digital and microfluidic technologies, enabling fully automated, cartridge-based systems. New England Biolabs (NEB) is a prominent supplier of LAMP reagents and enzymes, supporting a growing ecosystem of device manufacturers. Meanwhile, Thermo Fisher Scientific and Merck KGaA (operating as MilliporeSigma in the US and Canada) are expanding their molecular diagnostics portfolios to include LAMP-compatible platforms, reflecting the method’s increasing clinical acceptance.
Regulatory support and public health initiatives are also catalyzing market expansion. The World Health Organization’s ongoing endorsement of rapid molecular diagnostics for tuberculosis, malaria, and other diseases is prompting governments and NGOs to invest in LAMP-based solutions. Manufacturers are responding by developing rugged, battery-operated devices suitable for field deployment, with companies like Genomictree and OptiGene (now part of the Novacyt Group) actively innovating in this space.
Looking ahead to the next few years, the LAMP diagnostic equipment market is expected to benefit from continued R&D investment, particularly in multiplexing capabilities and integration with smartphone-based readouts. Strategic partnerships between reagent suppliers, device manufacturers, and healthcare providers are anticipated to accelerate commercialization and adoption. As the global focus on pandemic preparedness and antimicrobial resistance intensifies, LAMP’s role as a rapid, accessible, and cost-effective diagnostic tool is set to expand, positioning the sector for robust growth through 2025 and beyond.
Global Market Size, Segmentation, and 2025–2030 Growth Forecasts
The global market for Loop-Mediated Isothermal Amplification (LAMP) diagnostic equipment is poised for robust growth from 2025 through 2030, driven by increasing demand for rapid, sensitive, and cost-effective molecular diagnostics. LAMP technology, which enables nucleic acid amplification under isothermal conditions, has gained significant traction in clinical diagnostics, veterinary applications, food safety, and environmental monitoring. The COVID-19 pandemic accelerated adoption, and the momentum continues as healthcare systems worldwide prioritize decentralized and point-of-care (POC) testing.
In 2025, the LAMP diagnostic equipment market is estimated to be valued in the low single-digit billions (USD), with projections indicating a compound annual growth rate (CAGR) in the range of 10–15% through 2030. This expansion is underpinned by the increasing prevalence of infectious diseases, the need for rapid outbreak response, and the growing penetration of molecular diagnostics in low-resource settings. The market is segmented by product type (benchtop analyzers, portable/POC devices, and consumables), end-user (hospitals, diagnostic laboratories, research institutes, and field testing), and application (human diagnostics, veterinary, food safety, and environmental testing).
Key manufacturers are investing in automation, miniaturization, and integration of LAMP platforms with digital connectivity. Eiken Chemical Co., Ltd., the pioneer of LAMP technology, remains a global leader, offering the Loopamp series and collaborating with international partners to expand access. New England Biolabs supplies LAMP reagents and kits, supporting both research and clinical applications. Hiberna and Genomtec are notable for their portable, battery-operated LAMP devices targeting POC and field diagnostics. Thermo Fisher Scientific and Merck KGaA have expanded their molecular diagnostics portfolios to include LAMP-based solutions, leveraging global distribution networks.
Geographically, Asia-Pacific leads in market share, propelled by high disease burden, government initiatives, and local manufacturing. Europe and North America follow, with strong adoption in clinical and food safety sectors. Emerging markets in Africa and Latin America are expected to see the fastest growth, supported by international funding and technology transfer initiatives.
Looking ahead, the LAMP diagnostic equipment market is expected to benefit from ongoing R&D in multiplexing, lyophilized reagents for ambient storage, and integration with smartphone-based readouts. Regulatory harmonization and public-private partnerships will further accelerate market penetration. By 2030, LAMP is anticipated to be a mainstay in decentralized diagnostics, with equipment manufacturers playing a pivotal role in global health preparedness and response.
Technological Innovations in LAMP Diagnostic Equipment
The landscape of Loop-Mediated Isothermal Amplification (LAMP) diagnostic equipment manufacturing is undergoing rapid technological transformation as of 2025, driven by the demand for rapid, accurate, and field-deployable molecular diagnostics. LAMP technology, which enables nucleic acid amplification at a constant temperature, has spurred innovation in both instrument design and reagent formulation, with a focus on portability, automation, and integration with digital platforms.
Key manufacturers are introducing next-generation LAMP devices that emphasize user-friendliness and minimal sample preparation. For instance, Eiken Chemical Co., Ltd., the original developer of the LAMP method, continues to refine its Loopamp series, integrating features such as real-time fluorescence detection and compact, battery-powered operation. Their systems are widely adopted in clinical, veterinary, and food safety applications, and ongoing R&D is focused on multiplexing capabilities and connectivity for remote data sharing.
Another major player, New England Biolabs, supplies both LAMP reagents and instrumentation, supporting the development of point-of-care (POC) solutions. Their WarmStart LAMP kits are optimized for compatibility with portable devices, and the company collaborates with hardware manufacturers to ensure seamless integration. In 2025, NEB is expected to expand its partnerships to accelerate the deployment of LAMP-based diagnostics in low-resource settings.
Emerging companies are also contributing to the sector’s dynamism. Genelyzer and OptiGene are notable for their compact, field-ready LAMP platforms. OptiGene’s Genie series, for example, is recognized for its rapid turnaround and robust performance in diverse environments, from clinical labs to border biosecurity checkpoints. These systems are increasingly being equipped with wireless connectivity and cloud-based result management, reflecting the broader trend toward digital health integration.
Automation and microfluidics are at the forefront of innovation. Companies like Abbott are investing in automated sample-to-answer LAMP platforms, aiming to reduce operator intervention and error. Integration with smartphone-based readers and AI-driven result interpretation is anticipated to become mainstream by 2026, further democratizing access to molecular diagnostics.
Looking ahead, the LAMP diagnostic equipment market is expected to see continued miniaturization, enhanced multiplexing (simultaneous detection of multiple targets), and improved reagent stability for ambient storage. The convergence of LAMP technology with digital health infrastructure and telemedicine platforms is poised to expand its reach, particularly in decentralized and resource-limited settings. As regulatory approvals for LAMP-based devices increase globally, manufacturers are scaling up production and investing in sustainable, cost-effective manufacturing processes to meet growing demand.
Competitive Landscape: Leading Manufacturers and New Entrants
The competitive landscape for Loop-Mediated Isothermal Amplification (LAMP) diagnostic equipment manufacturing in 2025 is characterized by a mix of established molecular diagnostics companies and innovative new entrants, each vying to address the growing demand for rapid, sensitive, and field-deployable nucleic acid testing solutions. The sector is witnessing increased investment and product development, driven by the need for decentralized diagnostics in infectious disease management, food safety, and environmental monitoring.
Among the established leaders, Eiken Chemical Co., Ltd. remains a pivotal player, having pioneered the original LAMP technology and continuing to supply both reagents and dedicated equipment such as the Loopamp series. Eiken’s global partnerships and licensing agreements have enabled the proliferation of LAMP-based diagnostics, particularly in resource-limited settings. Another major manufacturer, New England Biolabs, supplies a broad range of LAMP reagents and has expanded its portfolio to include ready-to-use kits and protocols, supporting both research and clinical applications.
In the instrumentation segment, OptiGene Limited has established itself as a key supplier of LAMP diagnostic platforms, notably the Genie series, which are widely used for point-of-care and field testing. The company’s systems are recognized for their portability and rapid turnaround times, making them suitable for outbreak response and decentralized testing scenarios. Hiberna and Taiwan Advanced Nanotech Inc. (TANBead) are also active in the development of automated LAMP platforms, focusing on integration with sample preparation and data management.
Recent years have seen the entry of new players leveraging advances in microfluidics, digital detection, and connectivity. Startups such as Molbio Diagnostics have gained traction with compact, battery-operated LAMP devices tailored for use in remote and low-infrastructure environments. Molbio’s Truelab platform, for example, has been deployed in large-scale infectious disease screening programs, demonstrating the scalability and adaptability of LAMP technology.
Looking ahead, the competitive landscape is expected to intensify as more companies enter the market, spurred by the ongoing need for rapid diagnostics in public health and the increasing adoption of LAMP in veterinary, food, and environmental sectors. Strategic collaborations between manufacturers, reagent suppliers, and digital health companies are anticipated to accelerate the development of integrated, user-friendly LAMP diagnostic solutions. The focus will likely remain on enhancing automation, multiplexing capabilities, and connectivity to laboratory information systems, positioning LAMP as a cornerstone technology in the evolving molecular diagnostics ecosystem.
Regulatory Environment and Quality Standards (e.g., FDA, CE Mark)
The regulatory environment for Loop-Mediated Isothermal Amplification (LAMP) diagnostic equipment manufacturing is evolving rapidly as the technology becomes more widely adopted for point-of-care and laboratory-based molecular diagnostics. In 2025, manufacturers must navigate a complex landscape of international and national regulations, with particular attention to the requirements set by the U.S. Food and Drug Administration (FDA), the European Union’s CE Marking process, and other regional authorities.
In the United States, LAMP diagnostic devices intended for clinical use are classified as in vitro diagnostic (IVD) medical devices and are subject to FDA oversight. Manufacturers must typically submit a 510(k) premarket notification or, in some cases, a De Novo request, demonstrating substantial equivalence or novel safety and effectiveness, respectively. The FDA’s focus on analytical and clinical validation, manufacturing quality systems (21 CFR Part 820), and post-market surveillance remains stringent. During the COVID-19 pandemic, several LAMP-based assays received Emergency Use Authorization (EUA), but as of 2025, permanent market access requires full regulatory submissions. Companies such as Eiken Chemical Co., Ltd., a pioneer in LAMP technology, and New England Biolabs, a major supplier of LAMP reagents, have experience navigating these pathways for their products.
In the European Union, LAMP diagnostic equipment falls under the In Vitro Diagnostic Regulation (IVDR, Regulation (EU) 2017/746), which became fully applicable in May 2022. The IVDR imposes more rigorous requirements for clinical evidence, performance evaluation, and post-market surveillance compared to the previous IVDD. Manufacturers must work with Notified Bodies to obtain CE Marking, demonstrating conformity with essential requirements, including risk management and quality management systems (ISO 13485). Companies such as Hiberna and Genomtec are among those actively pursuing or holding CE Marked LAMP-based diagnostic platforms.
Globally, regulatory harmonization efforts are ongoing, with organizations like the International Medical Device Regulators Forum (IMDRF) promoting convergence of standards. In Asia, countries such as Japan and China have their own regulatory frameworks, with Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) and China’s National Medical Products Administration (NMPA) requiring local clinical data and quality documentation. Eiken Chemical Co., Ltd. is notable for its extensive regulatory experience in Japan and international markets.
Looking ahead, the regulatory outlook for LAMP diagnostic equipment is expected to become more robust, with increased scrutiny on analytical performance, cybersecurity (for digital platforms), and supply chain transparency. Manufacturers are investing in compliance infrastructure and quality management systems to meet these evolving standards, ensuring that LAMP-based diagnostics remain reliable and accessible in diverse healthcare settings.
Applications: Infectious Disease, Food Safety, and Beyond
Loop-Mediated Isothermal Amplification (LAMP) diagnostic equipment has rapidly evolved as a cornerstone technology for nucleic acid detection, with significant applications in infectious disease diagnostics, food safety, and other sectors. As of 2025, the manufacturing landscape for LAMP-based diagnostic devices is characterized by a focus on portability, automation, and integration with digital health platforms, reflecting the growing demand for rapid, accurate, and decentralized testing solutions.
In the field of infectious disease, LAMP diagnostic equipment is increasingly deployed for point-of-care (POC) testing of pathogens such as SARS-CoV-2, influenza, tuberculosis, and malaria. Manufacturers like Eiken Chemical Co., Ltd., the original developer of the LAMP method, continue to expand their product lines, offering both benchtop and portable LAMP devices. Their Loopamp™ series is widely used in clinical laboratories and field settings, with ongoing updates to support multiplexing and digital readouts. Similarly, New England Biolabs supplies LAMP reagents and supports instrument development through partnerships, enabling integration into automated diagnostic platforms.
Food safety is another major application area, where LAMP-based equipment is utilized for the detection of foodborne pathogens such as Salmonella, Listeria, and E. coli. Companies like bioMérieux and Thermo Fisher Scientific are actively involved in developing and supplying LAMP-compatible instruments and kits tailored for food industry laboratories. These systems are designed for high-throughput screening and rapid turnaround, supporting compliance with increasingly stringent food safety regulations worldwide.
Beyond infectious disease and food safety, LAMP diagnostic equipment is being adapted for veterinary diagnostics, environmental monitoring, and agricultural pathogen detection. For example, Genomadix (formerly Spartan Bioscience) has developed portable LAMP-based analyzers for field use, targeting both human and animal health applications. The trend toward miniaturization and connectivity is evident, with manufacturers incorporating wireless data transmission and cloud-based result management to facilitate remote diagnostics and epidemiological surveillance.
Looking ahead to the next few years, the outlook for LAMP diagnostic equipment manufacturing is robust. The sector is expected to benefit from continued investment in decentralized healthcare, the expansion of global disease surveillance networks, and the need for rapid response to emerging pathogens. Manufacturers are likely to focus on further reducing device size, increasing assay multiplexing capabilities, and enhancing user-friendliness to support broader adoption in resource-limited settings. Strategic collaborations between reagent suppliers, instrument manufacturers, and digital health companies will play a key role in shaping the next generation of LAMP diagnostic solutions.
Supply Chain, Manufacturing Challenges, and Solutions
The manufacturing and supply chain landscape for Loop-Mediated Isothermal Amplification (LAMP) diagnostic equipment in 2025 is shaped by both persistent challenges and innovative solutions. As demand for rapid, point-of-care molecular diagnostics continues to rise—driven by infectious disease surveillance, food safety, and veterinary applications—manufacturers are under pressure to scale production while maintaining quality and regulatory compliance.
A key challenge remains the sourcing and integration of specialized components, such as isothermal heating modules, optical detection systems, and microfluidic cartridges. Global supply chain disruptions, which began during the COVID-19 pandemic, continue to impact the availability of critical electronic and plastic parts. Leading LAMP equipment manufacturers, such as Eiken Chemical Co., Ltd.—the original developer of LAMP technology—have responded by diversifying their supplier base and investing in local manufacturing capabilities to reduce dependency on single-source suppliers.
Another significant issue is the need for stringent quality control and regulatory compliance, especially as LAMP devices are increasingly adopted in clinical settings. Companies like New England Biolabs and Merck KGaA (operating as MilliporeSigma in the US and Canada) have implemented advanced automation and digital tracking systems in their manufacturing lines to ensure batch-to-batch consistency and traceability. These measures are crucial for meeting the requirements of regulatory bodies such as the US FDA and the European Medicines Agency.
To address the challenge of rapid scale-up during outbreak situations, some manufacturers are adopting modular and flexible manufacturing approaches. For example, Genomictree, Inc. and OptiGene Limited have developed compact, scalable production lines that can be quickly reconfigured to meet surges in demand for specific LAMP assays or device formats. This flexibility is expected to be a key differentiator in the coming years, as the market for decentralized diagnostics expands.
Looking ahead, the outlook for LAMP diagnostic equipment manufacturing is positive, with continued investment in automation, supply chain resilience, and regulatory harmonization. Industry collaborations—such as those between equipment manufacturers and reagent suppliers—are expected to further streamline production and reduce lead times. As more countries prioritize domestic manufacturing of critical diagnostics, regional hubs are likely to emerge, reducing logistical bottlenecks and enhancing global health security.
Regional Analysis: North America, Europe, Asia-Pacific, and Emerging Markets
The global landscape for Loop-Mediated Isothermal Amplification (LAMP) diagnostic equipment manufacturing is characterized by dynamic regional developments, with North America, Europe, Asia-Pacific, and emerging markets each contributing distinctively to the sector’s growth and innovation trajectory in 2025 and the coming years.
North America remains a leading hub for LAMP diagnostic equipment manufacturing, driven by robust R&D infrastructure, established biotechnology firms, and a strong regulatory framework. The United States, in particular, is home to key players such as Thermo Fisher Scientific and New England Biolabs, both of which have expanded their LAMP assay portfolios and instrument offerings. These companies are investing in automation and integration of LAMP platforms for point-of-care (POC) diagnostics, targeting infectious diseases and genetic testing. The region’s focus on rapid, decentralized testing—accelerated by the COVID-19 pandemic—continues to drive demand for portable and user-friendly LAMP devices.
Europe is witnessing significant advancements in LAMP technology, supported by collaborative research initiatives and a growing emphasis on decentralized healthcare. Companies such as Eppendorf and QIAGEN are actively developing LAMP-based diagnostic solutions, with a focus on integrating digital connectivity and data management features. The European Union’s regulatory harmonization efforts are expected to streamline market entry for new LAMP devices, while public health agencies prioritize rapid diagnostics for antimicrobial resistance and emerging pathogens. The region’s strong academic-industry partnerships are fostering innovation in both instrument design and assay development.
Asia-Pacific is emerging as a high-growth region for LAMP diagnostic equipment manufacturing, propelled by increasing healthcare investments, expanding biotechnology sectors, and a rising burden of infectious diseases. Japan and China are at the forefront, with companies like Eiken Chemical Co., Ltd.—a pioneer in LAMP technology—scaling up production and distribution of LAMP-based diagnostic kits and instruments. The region’s focus on affordable, rapid diagnostics for rural and resource-limited settings is spurring the development of compact, battery-operated LAMP devices. Government initiatives to strengthen disease surveillance and local manufacturing capabilities are expected to further accelerate market growth through 2025 and beyond.
Emerging markets in Latin America, Africa, and parts of Southeast Asia are increasingly adopting LAMP diagnostic equipment, often through partnerships with global manufacturers and non-governmental organizations. Local production is gradually increasing, supported by technology transfer agreements and capacity-building programs. The affordability, simplicity, and minimal infrastructure requirements of LAMP platforms make them particularly well-suited for these regions, where access to centralized laboratory facilities is limited. As international funding and public health priorities align, the adoption of LAMP diagnostics in emerging markets is projected to expand steadily in the coming years.
Strategic Partnerships, M&A, and Investment Trends
The landscape of Loop-Mediated Isothermal Amplification (LAMP) diagnostic equipment manufacturing in 2025 is characterized by a dynamic interplay of strategic partnerships, mergers and acquisitions (M&A), and targeted investments. These activities are driven by the growing demand for rapid, accurate, and decentralized molecular diagnostics, particularly in infectious disease detection, food safety, and environmental monitoring.
Several leading diagnostic and life science companies have intensified their focus on LAMP technology, recognizing its potential for point-of-care and field-deployable applications. Eiken Chemical Co., Ltd., the original developer of LAMP, continues to play a pivotal role in the sector, both through direct manufacturing and by licensing its core LAMP patents to global partners. Eiken’s collaborations with diagnostic firms and public health organizations have enabled the proliferation of LAMP-based platforms worldwide.
Strategic partnerships have become a hallmark of the sector. For instance, New England Biolabs (NEB), a major supplier of LAMP reagents and enzymes, has established alliances with instrument manufacturers to ensure compatibility and performance optimization. NEB’s partnerships extend to both established diagnostic companies and emerging startups, facilitating the integration of LAMP chemistry into automated and portable devices.
M&A activity is also shaping the competitive landscape. In recent years, several mid-sized diagnostic equipment manufacturers have been acquired by larger multinational corporations seeking to expand their molecular diagnostics portfolios. Companies such as Thermo Fisher Scientific and QIAGEN have demonstrated interest in LAMP technology, either through direct acquisition of LAMP-focused startups or by forming joint ventures to accelerate product development and market entry. These moves are often motivated by the need to address emerging infectious diseases and to diversify beyond traditional PCR-based platforms.
Investment trends in 2025 indicate robust venture capital and corporate funding flowing into LAMP diagnostic equipment startups, particularly those developing miniaturized, user-friendly devices for decentralized testing. The COVID-19 pandemic catalyzed this trend, and ongoing concerns about global health security continue to attract investment. Notably, companies like Eiken Chemical Co., Ltd. and New England Biolabs are not only investing in internal R&D but also supporting external innovation through incubator programs and co-development agreements.
Looking ahead, the next few years are expected to see further consolidation as established players seek to secure intellectual property, expand manufacturing capabilities, and access new markets. Strategic alliances between reagent suppliers, instrument manufacturers, and digital health companies will likely accelerate the commercialization of integrated LAMP diagnostic solutions, positioning the sector for sustained growth and technological advancement.
Future Outlook: Market Opportunities and Projected CAGR (2025–2030)
The future outlook for Loop-Mediated Isothermal Amplification (LAMP) diagnostic equipment manufacturing from 2025 through 2030 is marked by robust growth prospects, driven by increasing demand for rapid, accurate, and cost-effective molecular diagnostics. The LAMP technique’s ability to amplify nucleic acids under isothermal conditions, without the need for complex thermal cyclers, positions it as a preferred solution for point-of-care (POC) and decentralized testing environments. This is particularly relevant in infectious disease diagnostics, food safety, veterinary applications, and environmental monitoring.
Key manufacturers such as Eiken Chemical Co., Ltd.—the original developer of the LAMP method—continue to expand their product portfolios, focusing on automated and portable LAMP platforms. Eiken’s Loopamp™ series and associated reagents are widely adopted in clinical and field settings, and the company is investing in next-generation devices with enhanced multiplexing and connectivity features. Similarly, New England Biolabs (NEB) is a major supplier of LAMP reagents and kits, supporting both research and commercial diagnostic applications. NEB’s commitment to innovation is evident in its ongoing development of lyophilized and ready-to-use LAMP formulations, which are expected to further simplify workflow and expand market reach.
Another significant player, Merck KGaA (operating as MilliporeSigma in the US and Canada), provides critical raw materials and enzymes for LAMP assay development, supporting OEMs and diagnostic companies worldwide. Takara Bio Inc. is also active in this space, offering LAMP-based detection kits and collaborating with healthcare providers to validate new clinical applications.
The market is witnessing increased interest from emerging companies and startups, particularly those focused on integrating LAMP technology with microfluidics, smartphone-based detection, and digital health platforms. This trend is expected to accelerate as regulatory agencies, such as the World Health Organization and national health authorities, emphasize the need for scalable, decentralized diagnostic solutions in response to global health threats.
Looking ahead, the LAMP diagnostic equipment market is projected to achieve a compound annual growth rate (CAGR) in the high single digits to low double digits between 2025 and 2030, reflecting both expanding application areas and technological advancements. Growth will be particularly strong in Asia-Pacific and Africa, where the need for affordable, rapid diagnostics is acute. Strategic partnerships, investments in automation, and the development of multiplexed and digital LAMP platforms will be key drivers shaping the competitive landscape and enabling broader adoption of LAMP-based diagnostics worldwide.
Sources & References
- Eiken Chemical Co., Ltd.
- Thermo Fisher Scientific
- Genomictree
- Novacyt Group
- Genomtec
- Taiwan Advanced Nanotech Inc. (TANBead)
- bioMérieux
- Genomadix
- Eppendorf
- QIAGEN
- Takara Bio Inc.
